# Relief Cardiovascular

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/relief-cardiovascular

- Industry: Medical Devices & Equipment
- Headquarters: Costa Mesa, US
- Website: www.reliefcardio.com
- Total disclosed funding: $12M
- Latest round: Series A (Jan 8, 2025)
- Investors on record: 4

## About

Based in California, US, Relief Cardiovascular focuses on creating a closed-loop transcatheter implant to provide a solution for heart failure patients. In January 2025, Relief Cardiovascular raised USD 12 million in series A funding co-led by Advent Life Sciences and Broadview Ventures, with participation from Heartwork Human Capital, LLC, and Pacific Health Ventures. 

Relief Cardiovascular is a device designed to treat congestive heart failure. This device is a closed-loop implant that aims to improve patient outcomes by addressing the blood flow problems caused by the condition. The company targets hospitals and heart specialists who treat patients with congestive heart failure, a common and increasing health issue worldwide. Relief Cardiovascular focuses its efforts mainly in North America and Europe, where the need for advanced treatments is high. 

The company plans to use the January 2025 funding to facilitate the progression of the relief system into its initial human clinical trial.

## Funding rounds

- Series A, Jan 8, 2025, $12M — Broadview Ventures, Advent Life Sciences, Pacific Health Ventures, Heartwork Human Capital, LLC

## Investors

- Broadview Ventures (https://capitalatlas.ai/funds/broadview-ventures) — Series A
- Advent Life Sciences (https://capitalatlas.ai/funds/advent-life-sciences) — Series A
- Pacific Health Ventures (https://capitalatlas.ai/funds/pacific-health-ventures) — Series A
- Heartwork Human Capital, LLC — Series A